Transgender medicine - puberty suppression
- 781 Downloads
Puberty suppression is the reversible first step of endocrine medical treatment in transgender youth, and allows for two very important aspects of transgender management. Firstly, it buys the patient, family and their medical team time to fully evaluate the presence and persistence of gender dysphoria. Secondly, it successfully prevents the development of cis-gender unwanted secondary sexual characteristics. The latter, when present, almost certainly increase the burden of psychological co-morbidity for any transgender person. This management is modelled from treatment of gonadotropin-dependent precious puberty, with use of GnRH agonists at its core. With the increasing number of transgender youth treated, and the changing demographics of patients seeking medical care, providers are faced with the decision to start puberty blockade at younger ages than previous decades. This article will review the rationale behind puberty blockade for transgender children, the providers’ options for achieving this goal, the emerging literature for potential adverse effects on such an approach, as well as identify directions of potential future research.
KeywordsPuberty suppression Puberty blockade Transgender GnRH agonists Bone health Endocrine transgender care
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.Diagnostic and Statistical Manual of Mental Disorders, in Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Publishing; 2013.Google Scholar
- 45.Sun Pharmaceutical Industries, Inc. Leuprolide acetate injection [prescribing information]. Cranbury; 2014.Google Scholar
- 47.Abbvie, Inc. Lupron Depot-PED (leuprolide) [prescribing information]. North Chicago; 2017.Google Scholar
- 49.van der Sluis IM, Boot AM, Krenning EP, Drop SLS, de Muinck Keizer-Schrama SMPF. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab. 2002;87(2):506–12.CrossRefGoogle Scholar
- 52.Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese study group on central precocious puberty. J Clin Endocrinol Metab. 2005;90(3):1371–6.CrossRefGoogle Scholar
- 58.Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: Impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93(1):190–5.CrossRefGoogle Scholar
- 61.Fisher AD, Castellini G, Ristori J, Casale H, Giovanardi G, Carone N, et al. Who has the worst attitudes toward sexual minorities? Comparison of transphobia and homophobia levels in gender dysphoric individuals, the general population and health care providers. J Endocrinol Investig. 2017;40(3):263–73.CrossRefGoogle Scholar